MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

Search

Corbion NV

Avatud

SektorRahandus

18.42 0.71

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.94

Max

18.43

Põhinäitajad

By Trading Economics

Sissetulek

-10M

32M

Müük

-24M

622M

P/E

Sektori keskmine

14.953

54.048

Dividenditootlus

3.35

Kasumimarginaal

5.211

Töötajad

2,408

EBITDA

-10M

96M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+31.78% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.35%

4.84%

Turustatistika

By TradingEconomics

Turukapital

-18M

1.1B

Eelmine avamishind

17.71

Eelmine sulgemishind

18.42

Uudiste sentiment

By Acuity

22%

78%

36 / 441 Pingereas Finance

Corbion NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. märts 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23. märts 2026, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23. märts 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23. märts 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23. märts 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23. märts 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23. märts 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23. märts 2026, 22:42 UTC

Market Talk
Uudisväärsed sündmused

Global Equities Roundup: Market Talk

23. märts 2026, 22:42 UTC

Market Talk
Uudisväärsed sündmused

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23. märts 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23. märts 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23. märts 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23. märts 2026, 22:18 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23. märts 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23. märts 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23. märts 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. märts 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23. märts 2026, 21:10 UTC

Uudisväärsed sündmused

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23. märts 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk
Tulu
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Corbion NV Prognoos

Hinnasiht

By TipRanks

31.78% tõus

12 kuu keskmine prognoos

Keskmine 23.8 EUR  31.78%

Kõrge 28 EUR

Madal 19.6 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Corbion NV 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

36 / 441 Pingereas Rahandus

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Corbion NV

Corbion N.V. provides lactic acid and lactic acid derivatives, other ferment, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide. It offers ingredient solutions for the food, home and personal care, animal nutrition, supplements, pharmaceuticals, medical devices, and bioplastics markets. The company markets its products through a network of sales offices and distributors. The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was incorporated in 1919 and is headquartered in Amsterdam, the Netherlands.
help-icon Live chat